AstraZeneca Announced Imfinzii Plus Chemotherapy More Than Doubled Pathologic Complete Response Rate In Resectable Early-stage Gastric And Gastroesophageal Junction Cancers Versus Chemotherapy Alone
Portfolio Pulse from Charles Gross
AstraZeneca announced positive results from the interim analysis of the MATTERHORN Phase III trial. The trial showed that AstraZeneca's IMFINZI in combination with standard-of-care FLOT neoadjuvant chemotherapy demonstrated a significant improvement in the pathologic complete response for patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction cancers.
October 21, 2023 | 1:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AstraZeneca's positive trial results for IMFINZI could potentially boost its market position in the cancer treatment sector.
The positive results from the MATTERHORN Phase III trial indicate that AstraZeneca's IMFINZI, in combination with standard-of-care FLOT neoadjuvant chemotherapy, has a significant impact on the treatment of gastric and gastroesophageal junction cancers. This could potentially increase the demand for IMFINZI, thereby boosting AstraZeneca's market position and stock value in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100